{"filing":{"accession_number":"0001437749-26-026282","cik":"0001401667","ticker":"PBYI","company_name":"PUMA BIOTECHNOLOGY, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"pbyi20260608_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/pbyi20260608_8k.htm"},"events":[{"id":25752,"run_id":23372,"accession_number":"0001437749-26-026282","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Puma Biotechnology's financial results for Q2 2026 ended June 30, 2026. The filing explicitly states \"On August 6, 2026, Puma Biotechnology, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026\" and includes detailed GAAP and non-GAAP net income, revenue figures ($56.5M total revenue, $8.2M net income), and updated full-year 2026 guidance. The press release is furnished as Exhibit 99.1 and is typical of Item 2.02 earnings disclosures.","company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26663,"accession_number":"0001437749-26-026282","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Puma Biotechnology's financial results for Q2 2026 ended June 30, 2026. The filing explicitly states \"On August 6, 2026, Puma Biotechnology, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026\" and includes detailed GAAP and non-GAAP net income, revenue figures ($56.5M total revenue, $8.2M net income), and updated full-year 2026 guidance. The press release is furnished as Exhibit 99.1 and is typical of Item 2.02 earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:09.682945+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26663,"accession_number":"0001437749-26-026282","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Puma Biotechnology's financial results for Q2 2026 ended June 30, 2026. The filing explicitly states \"On August 6, 2026, Puma Biotechnology, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026\" and includes detailed GAAP and non-GAAP net income, revenue figures ($56.5M total revenue, $8.2M net income), and updated full-year 2026 guidance. The press release is furnished as Exhibit 99.1 and is typical of Item 2.02 earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:09.682945+00:00","company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","filing_date":"2026-08-06"}]}